Commentary

You have free access to this content

Human genome variation and pharmacogenetics†

  1. Bruce Gottlieb1,2,3,*

Article first published online: 10 MAR 2008

DOI: 10.1002/humu.20728

Issue

Human Mutation

Human Mutation

Special Issue: Focus on Pharmacogenetics

Volume 29, Issue 4, pages 453–455, April 2008

Additional Information

How to Cite

Gottlieb, B. (2008), Human genome variation and pharmacogenetics. Hum. Mutat., 29: 453–455. doi: 10.1002/humu.20728

Author Information

  1. 1

    Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada

  2. 2

    Department of Human Genetics, McGill University, Montreal, Quebec, Canada

  3. 3

    Department of Biology, John Abbott College, Ste Anne de Bellvue, Quebec, Canada

*Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote Ste. Catherine Road, Montreal, Quebec, Canada H3T 1E2

  1. †

    For the Focus Section on Pharmacogenetics

Publication History

  1. Issue published online: 10 MAR 2008
  2. Article first published online: 10 MAR 2008
  3. Manuscript Accepted: 18 DEC 2007
  4. Manuscript Received: 11 DEC 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (76K)

REFERENCES

  • de Smith AJ, Tsalenko A, Sampas N, Scheffer A, Yamada NA, Tsang P, Ben-Dor A, Yakhini Z, Ellis RJ, Bruhn L, Laderman S, Froguel P, Blakemore AIF. 2007. Array CGH analysis of copy number variation identifies 1284 new genes variant in healthy white males: implications for association studies of complex diseases. Hum Mol Genet 16:2783–2794.
  • Fimmel S, Kurfurst R, Bonte F, Zouboulis CC. 2007. Responsiveness to androgens and effectiveness of antisense oligonucleotides against the androgen receptor on human epidermal keratinocytes is dependent on the age of the donor and the location of cell origin. Horm Metab Res 39:157–165.
  • Geretti AM. 2006. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. AIDS Rev 8:210–220.
  • Gottlieb B, Beitel LK, Trifiro M. 2001. Somatic mosaicism and variable expressivity. Trends Genet 17:79–82.
  • Gottlieb B, Beitel LK, Trifiro M. 2007. Will knowledge of human genome variation result in changing cancer paradigms? Bioessays 29:678–685.
    Direct Link:
  • Grant SF, Hakonarson H. 2007. Recent developments in pharmacogenomics: from candidate genes to genome-wide association studies. Expert Rev Mol Diagn 7:371–393.
  • Haber DA, Settleman J. 2007. Cancer: drivers and passengers. Nature 446:145–146.
  • Jarjanazi H, Kiefer J, Savas S, Biollais L, Pabalan N, Ibrahim-Zada I, Tuzmen S, Mousses S, Ozcelik H. 2008. Discovery of genetic profiles impacting response to chemotherapy: application to Gemcitabine. Hum Mutat 29:461–467.
    Direct Link:
  • Kehrer-Sawatski H. 2007. What a difference copy number variation makes. Bioessays 29:311–313.
    Direct Link:
  • Owen PR, Altman RB, Klein TE. 2008. PharmaGKB and the International Warfarin Pharmacogenetics Consortium: the changing role of the pharmacogenomic databases and single drug pharmacogenetics. Hum Mutat 29:456–460.
    Direct Link:
Get PDF (76K)